Details
Stereochemistry | RACEMIC |
Molecular Formula | C14H17NO2.ClH |
Molecular Weight | 267.751 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.C(OC1=C2CC=CC2=CC=C1)C3CNCCO3
InChI
InChIKey=KEBHLNDPKPIPLI-UHFFFAOYSA-N
InChI=1S/C14H17NO2.ClH/c1-3-11-4-2-6-14(13(11)5-1)17-10-12-9-15-7-8-16-12;/h1-4,6,12,15H,5,7-10H2;1H
Molecular Formula | C14H17NO2 |
Molecular Weight | 231.2903 |
Charge | 0 |
Count |
|
Stereochemistry | RACEMIC |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Optical Activity | ( + / - ) |
Molecular Formula | ClH |
Molecular Weight | 36.461 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionCurator's Comment: description was created based on several sources, including:
http://pmmp.cnki.net/Resources/CDDPdf/med%5Cbase%5C%E7%A5%9E%E7%BB%8F%E7%B3%BB%E7%BB%9F%E8%8D%AF%E7%89%A9%5C5795.pdf | https://www.ncbi.nlm.nih.gov/pubmed/518676 |https://www.reddit.com/r/Nootropics/comments/17qpe4/indeloxazine_information/
Curator's Comment: description was created based on several sources, including:
http://pmmp.cnki.net/Resources/CDDPdf/med%5Cbase%5C%E7%A5%9E%E7%BB%8F%E7%B3%BB%E7%BB%9F%E8%8D%AF%E7%89%A9%5C5795.pdf | https://www.ncbi.nlm.nih.gov/pubmed/518676 |https://www.reddit.com/r/Nootropics/comments/17qpe4/indeloxazine_information/
Indeloxazine is a neuroleptic, originally developed and marketed in Japan. It is indicated to allay autonomic hyperactivity following cerebral infarction, cerebral haemorrhage or atherosclerosis. It was found to be a weak inhibitor of both type A and type B monoamine oxidases. Indeloxazine-induced facilitation of acetylcholine release in frontal cortex is mediated by endogenous 5-HT and involves at least in part cortical 5-HT4 receptors. As a potential teratogen, Indeloxazine must not be consumed or handled by pregnant or nursing women, or by women who might become pregnant. It was removed from the market reportedly for lack of effectiveness.
Originator
Sources: https://www.google.com/patents/DE2601703C2
Curator's Comment: http://www.chemdrug.com/article/9/3288/16437231.html
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2993 Sources: https://www.ncbi.nlm.nih.gov/pubmed/518676 |
260.0 µM [IC50] | ||
Target ID: CHEMBL3358 Sources: https://www.ncbi.nlm.nih.gov/pubmed/518676 |
90.0 µM [IC50] | ||
Target ID: CHEMBL4317 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9453456 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Palliative | Elen Approved UseIndeloxazine was commonly used to treat a psychiatric symptoms, such as memory impairment or emotional disturbance associated with a cerebral infarction, hemorrhage or cerebral arteriosclerosis. |
|||
Palliative | Elen Approved UseIndeloxazine was commonly used to treat a psychiatric symptoms, such as memory impairment or emotional disturbance associated with a cerebral infarction, hemorrhage or cerebral arteriosclerosis. |
|||
Palliative | Elen Approved UseIndeloxazine was commonly used to treat a psychiatric symptoms, such as memory impairment or emotional disturbance associated with a cerebral infarction, hemorrhage or cerebral arteriosclerosis. |
Sample Use Guides
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/518676
YM-08054-1 at concentrations of less than 1 uM considerably inhibited 5-HT uptake by synaptosomes from rat whole brain as well as noradrenaline (NA) uptake by synaptosomes from rat hippocampus. It blocks the reuptake of noradrenaline with IC50 of 3.2 uM and of serotonin with IC50 of 0.71 uM.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:00:11 GMT 2023
by
admin
on
Fri Dec 15 15:00:11 GMT 2023
|
Record UNII |
15QZ6NE84E
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C265
Created by
admin on Fri Dec 15 15:00:11 GMT 2023 , Edited by admin on Fri Dec 15 15:00:11 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
C81478
Created by
admin on Fri Dec 15 15:00:11 GMT 2023 , Edited by admin on Fri Dec 15 15:00:11 GMT 2023
|
PRIMARY | |||
|
47517
Created by
admin on Fri Dec 15 15:00:11 GMT 2023 , Edited by admin on Fri Dec 15 15:00:11 GMT 2023
|
PRIMARY | |||
|
SUB02663MIG
Created by
admin on Fri Dec 15 15:00:11 GMT 2023 , Edited by admin on Fri Dec 15 15:00:11 GMT 2023
|
PRIMARY | |||
|
15QZ6NE84E
Created by
admin on Fri Dec 15 15:00:11 GMT 2023 , Edited by admin on Fri Dec 15 15:00:11 GMT 2023
|
PRIMARY | |||
|
100000086982
Created by
admin on Fri Dec 15 15:00:11 GMT 2023 , Edited by admin on Fri Dec 15 15:00:11 GMT 2023
|
PRIMARY | |||
|
DTXSID60983582
Created by
admin on Fri Dec 15 15:00:11 GMT 2023 , Edited by admin on Fri Dec 15 15:00:11 GMT 2023
|
PRIMARY | |||
|
m1196
Created by
admin on Fri Dec 15 15:00:11 GMT 2023 , Edited by admin on Fri Dec 15 15:00:11 GMT 2023
|
PRIMARY | Merck Index | ||
|
CHEMBL2105022
Created by
admin on Fri Dec 15 15:00:11 GMT 2023 , Edited by admin on Fri Dec 15 15:00:11 GMT 2023
|
PRIMARY | |||
|
15QZ6NE84E
Created by
admin on Fri Dec 15 15:00:11 GMT 2023 , Edited by admin on Fri Dec 15 15:00:11 GMT 2023
|
PRIMARY | |||
|
1311672
Created by
admin on Fri Dec 15 15:00:11 GMT 2023 , Edited by admin on Fri Dec 15 15:00:11 GMT 2023
|
PRIMARY | RxNorm | ||
|
C020852
Created by
admin on Fri Dec 15 15:00:11 GMT 2023 , Edited by admin on Fri Dec 15 15:00:11 GMT 2023
|
PRIMARY | |||
|
65043-22-3
Created by
admin on Fri Dec 15 15:00:11 GMT 2023 , Edited by admin on Fri Dec 15 15:00:11 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |